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cense. httpAbstract Background: Somatic mutations in isocitrate dehydrogenase 1 (IDH1) gene occur fre-
quently in primary brain tumors. Recently theses mutations were demonstrated in acute myeloid
leukemia (AML). So far, assessment of these mutations relied on the DNA sequencing technique.
Aim of the work: The aim of this study was to detect somatic mutations in IDH1 gene using mis-
matched primers suitable for endonuclease based detection, without the need for DNA sequencing,
and to estimate its prognostic value, on patients with de novo AML.
Methods: Residual DNA extracted from pretreatment bone marrow (BM) samples of 100 patients
with de novo AML was used. The polymerase chain reaction-restriction fragment length polymor-
phism method (PCR-RFLP) was adapted to IDH1gene, codon 132 mutations screening.
Results: The frequency of IDH1 mutations was 13%. In the non-acute promyelocytic leukemia
group (non-APL), IDH1 mutations were signiﬁcantly associated with FLT3-ITD negative patients
(p= 0.03). Patients with IDH1 mutations did not achieve complete remission (CR). There was a
trend for shorter overall survival (OS) in patients with IDH1 mutation compared to those with wild
type (p= 0.08).
Conclusion: IDH1 mutations are recurring genetic alterations in AML and they may have unfavor-
able impact on clinical outcome in adult AML. The PCR-RFLP method allows for a fast, inexpen-
sive, and sensitive method for the detection of IDH1 mutations in AML.
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Cytogenetic aberrations are the most important prognostic
parameter in AML [1]. Various chromosomal aberrations
have been identiﬁed in AML patients, and are associated
with uniquely distinct clinical entities and prognostic relevance
[2].ational Cancer Institute, Cairo University.
.001
44 G.M. Elsayed et al.Approximately 50% of patients with AML show a normal
karyotype (CN-AML). Although no aberrations can be
detected in standard cytogenetic analysis, CN-AML is a heter-
ogeneous disease [3].
To date, a wide assortment of gene mutations that normally
function in the cell proliferation, differentiation and survival
have been identiﬁed in CN-AML. The most frequent of these
aberrations is mutations in the nucleophosmin gene (NPM1)
which are present in approximately 50% of these patients.
Other common genetic lesions are internal tandem duplication
(ITD) in the cytokine receptor gene FLT 3 (approximately
20–30% of CN-AML), loss-of-function mutations in the
Wilm’s-tumor gene (WT1) and the CEBPA gene, which encode
for the myeloid transcription factor CCAAT/enhancer binding
protein alpha C/EBPa (both present in approximately 10% of
CN-AML) [3].
Among these genetic alterations, recurrent somatic muta-
tions in the nicotinamide adenine dinucleotide phosphate
(NADPH)-dependent isocitrate dehydrogenase 1 (IDH1) gene,
affecting codon R132 (p.Arg132Cys), are special in that the
gene is involved in metabolism, rather than signaling pathway
or transcription factor [4].
There are three IDH1 isoforms; IDH1 is in the cytoplasm
whereas IDH2 and IDH3 are localized in the mitochondria.
Normally, the IDH1 enzymes catalyze oxidative decarboxyl-
ation of isocitrate to a-ketoglutarate (a-KG), utilizing nicotin-
amide adenine dinucleotide (NAD) or NAD phosphate
(NADP) as a cofactor to generate NADH or NADPH, respec-
tively, both metabolites ultimately derived from glucose in the
course of generating energy for the cell [5].
IDH1 mutations were ﬁrst described in >70% malignant
gliomas and were associated with a better response to therapy
than those with wild type IDH1 gene, and were associated with
reduced enzymatic activity of the encoded protein [6]. Meta-
bolic proﬁling has identiﬁed a neomorphic activity in the pres-
ence of the mutant enzyme, namely generation of a novel
onco-metabolite, D-2-hydroxyglutarate (D-2HG) [1].
D-2HG is structurally similar to aKG, and thus may act
through the inhibition of enzymes requiring aKG. Large-scale
analyses of genome-wide DNA methylation patterns in human
gliomas found that IDH1/2 mutations were associated with a
highly speciﬁc DNA methylation proﬁle [7].
It has been postulated that the changes in methylation may
be due to D-2HG-mediated inhibition of multiple aKG-depen-
dent dioxygenases, including the Tet oncogene family (TET) of
5-methylcytosine (5mC) hydroxylases and histone establish the
glioma hypermethylator phenotype and result in a block to cell
differentiation [8].
Recently, IDH1 mutation was identiﬁed as a new genetic
alteration in newly diagnosed AML patients with a frequency
of 8.3% and 16% of total AML patients and those with a CN-
AML, respectively [9]. It is thought that consumption of
NADPH and production of 2HG could contribute to leuko-
mogenesis, which might be due to the DNA damage via the
elevated levels of reactive oxygen species and/or the induction
of DNA methylation via the disruption of TET2 function [3].
There have been several studies investigating the prognostic
signiﬁcance of IDH1 mutation status in AML patients, some
of which demonstrated the negative prognostic effect of
IDH1 mutations [6,10–11], whereas others found no clinical
outcome difference between patients with and without IDH1
mutations [3,9,12,13]. In addition, multivariate analysis ofCN-AML suggested that IDH1 mutations predict poor out
come in the subset of patients with mutant NPM1 without
FLT3-ITD [10]. The prognostic value of IDH1 mutations in
AML remains to be further evaluated.
Detection of IDH1 mutations so far relied on genomic
sequencing. The fact that these mutations are limited to a small
hot spot region in exon 4 in one codon creates an opportunity
for the application of a simple test based on restriction diges-
tion. Unfortunately, IDH1gene does not contain suitable sites
for restriction endonuclease-based analysis of codon 132 [14].
Mismatched primers to create suitable restriction sites for
wild-type and mutant sequences were generated. This
approach termed as derived cleaved ampliﬁed polymorphic
sequence analysis (dCAPS) has previously been described
[15]. The most common ﬁve mutations (R132H, R132C,
R132G, R132L, and R132S) leading to different amino acid
(AA) exchange were detected by Meyer et al. [16] using
mismatched primers and (PCR-RFLP) based detection for
IDH1 mutations on glioma patients. In contrast, the set of
primers used by Bujko et al. [14] detected the most frequent
two IDH1 mutations, R132H (395G > A) and R132C
(394C > T) [17].
In the present study, we aimed to use the previously gener-
ated mismatched primers suitable for endonuclease based
detection of hot spot mutations in codon 132 of IDH1 gene
on AML patients, and to characterize the frequency, clinical
and biologic features of AML patients with IDH1 mutations,
and their correlation with FLT3-ITD mutation.
Patients and methods
Patients
In the period between March and December 2011, 100 young
adult patients (16–60 years old) with newly diagnosed AML,
were referred to the clinical pathology department, National
Cancer institute, Cairo University. Patients above 60 years
and younger than 16 years were excluded, and those with sec-
ondary AML or insufﬁcient samples to extract DNA were also
excluded from the study.
DNA was extracted from all patients for the routine analy-
sis of FLT3-ITD mutation using a QIAamp DNA extraction
kit (Qiagen, Hilden, Germany). Residual DNA was used for
IDH1 mutation detection according to an approved institu-
tional review board protocol. No patient included in our anal-
ysis received allogeneic bone marrow transplantation (BMT).
Pretreatment laboratory information was obtained from the
department’s laboratory information system.
Morphologic analysis
Diagnosis of AML was made using standards morphology and
cytochemistry, according to the FAB classiﬁcation [18].
IDH1 mutation detection
Exon 4 mutations in codon 132 were detected using PCR-
RFLP. Mismatched primers designed by Meyer et al. [16] were
used for ampliﬁcation. One set of primers was designed to
detect the presence or absence of IDH1 mutations in codon
132.
Prognostic value of IDH1 mutations identiﬁed 45PCR was performed in a 50 ll reaction volume, containing
10 pmol of each primer, pIDH1f-R132 50- TGG GTA A AA
CCT ATC ATC ATC GAT-30 and pIDH1r-132 50- TGT
GTT GAG ATG GAC GCC TA-30, 2.5 mM of MgCl2, and
100 ng of DNA using a Hot Taq DNA polymerase (Qiagen,
Hilden, Germany). Initial denaturation was carried at 94 C
for 2 min, followed by 35 cycles of 30 s each at 94 C, anneal-
ing for 30 s at 55 C and extension for 40 s at 72 C with a ﬁnal
extension step at 72 C for 5 min creating a 261 bp PCR prod-
uct. After ampliﬁcation, 20 ll of the PCR product was digested
using a FastDigest PvuI (Thermo scientiﬁc, Germany) enzyme
for 5 min at 37 C. Complete restriction of this PCR product
resulting in a single band upon electrophoretic separation con-
ﬁrms wild type sequence. Detection of two bands indicates a
mutation, (Fig. 1).
FLT3-ITD mutation detection
Exon 14 and 15 (previously designated exon 11 and 12) were
ampliﬁed from DNA as previously described by Schnittger et
al. [19]. The PCR product was analyzed on a standard 4% aga-
rose gel. A fragment of 328 base pair (bp) was produced from
wild-type (WT) alleles. Any patient with an additional higher
molecular weight size was considered to be positive for
FLT3-ITD. To calculate the allelic ratio (mutant/wild), we
used the BioDocAnalyze (BDA) software (Biometra,
Germany) for densitometric estimation of ethidium bromide-
stained agarose gels.
Fluorescent in situ hybridization (FISH) analysis for PML/
RARa
We used the PML/RARA Translocation Probe, Dual fusion
(Abbott, USA) created by the t (15; 17) (q24; q21), the RARa
labeled in green, and the PML gene labeled in red according to
the manufacturer’s instructions. Air dried slides were prepared
according to the cytogenetic technique from all bone marrow
samples. Slides were washed in 2 · SSC for 2 min at room tem-
perature followed by dehydration in an ethanol series (75%,
85% and 100%), each for 2 min, then were allowed to dry.Figure 1 (A) DNA from 5 patients with conﬁrmed DNA
sequence in codon 132 of IDH1 indicated on the top was ampliﬁed
with sequence speciﬁc mismatched primers.(B) Patients 1, 2 and 4
were wild type (single band) while 3 and 5 carried the mutation
(two bands) after complete restriction of PCR product using PvuI.
Fragment size in base pairs is given on the right.A total of 10 ll of probe mixture was spotted on the cell
sample, the coverslip was carefully placed and the edges were
carefully sealed with rubber cement. Slides were placed in
a Denaturing/ Hybridization System for FISH HyBrite
apparatus (Vysis, USA), at 75 C for 2 min. Then, they were
hybridized at 37 C overnight. The next day, the coverslip
was removed, a post-hybridization wash was performed and
10 ll of DAPI antifade solution was added and covered with
a coverslip. Slides were then placed in the dark for 10 min to
allow for color development, and then were viewed with
appropriate ﬁlters using a ﬂuorescence microscope (Olympus,
Germany) and FISH software. A minimum of 100 cells were
scored for signals [20].
Therapy
Patients were treated according to the standard AML protocol
of the NCI [21]. All patients received the 3 and 7 protocols
which consisted of adriamycin 30 mg/m2 for 3 days and
ARAC 100 mg/m2 by continuous infusion for 7 days. Patients
with AML (M3) received all trans-retinoic acid a (ATRA).
Further treatment of AML patients was according to their
risk group. Patients with favorable risk group were treated
with high dose ARAC containing usually HAM protocol
(ARAC 1 gm/m2 over 3 h infusion every 12 h (days 1–3) and
mitoxantrone 12 mg/m2 short infusion (days 3–5). If relapse
occurred, a second induction by HAM or AVVV protocol
was given. For the unfavorable risk group, HD-ARAC con-
taining regimen was given for 3 cycles. If relapse occurred
for this group of patients they were treated with palliative care
only. No patients in our study received allogeneic transplanta-
tion during complete remission.
For certain subgroups of AML, special treatment was used.
Patients with AML M5 have high risk of central nervous sys-
tem disease, so they were given triple intrathecal prophylaxis
(methotrexate 15 mg, ARAC 40 mg and dexamethasone
4 mg) every 8 weeks for a total of 6 injections with induction
treatment. If CNS disease was diagnosed at presentation, triple
intrathecal injections were given until CSF was free then; cra-
niospinal irradiation was given to be followed by intrathecal
injection of ARA-C and dexamethasone every 8 weeks for 7
doses.
For patients with AML M3, induction treatment consisted
of ATRA 45 mg/m2 oral daily in divided doses every 12 h until
complete remission or for a maximum of 90 days, and adria-
mycin 30 mg/m2 for 3 days every month for 3 courses. These
patients received maintenance treatment after complete remis-
sion with ATRA (45 mg/m2 oral daily for two weeks every
3 months for every 2 years) and 6 mercaptopurine and metho-
trexate for 2 years.
End points
Complete remission (CR) was deﬁned as a normocellular BM
containing less than 5% blasts and showing evidence of nor-
mal maturation of other marrow elements. Peripheral blood
regeneration was not a requirement, but 97% of cases deﬁned
as CR achieved a neutrophil count of 1 · 109/L and a platelet
count of 100 · 109/L.
Remission failures were classiﬁed by the clinicians as
either partial remission (deﬁned as 5–15% blasts or <5%
46 G.M. Elsayed et al.blasts but a hypocellular BM), resistant disease (RD)
(>15% blasts in the BM), or induction death (ID) (i.e., re-
lated to treatment or hypoplasia). When the clinician’s
evaluation was not available, deaths within 30 days of entry
were classiﬁed as (ID), and all other failures to achieve
remission as resistant disease (RD). OS end points were
measured from the date of diagnosis to death or last fol-
low-up [22].
Statistical analysis
SPSS package version 17.0 was used for data management.
Mann–Whitney was used to compare numerical variable in
two independent groups. The Chi-square or Fisher’s exact test
was used to test proportion independence. The Kaplan–Meier
method was used to estimate survival and log rank compared
curves. P values 60.05 were considered signiﬁcant.Results
Frequency of IDH1 mutations
Patients included 47 males and 53 females with a median age of
53 years (range, 16–60 years). In a total group of 100 AML
cases, 13 cases (13%) of IDH1 mutation were identiﬁed by
PCR-RFLP. When excluding AML (M3) patients from the
analysis, in the non-APL group, IDH1 mutation was detected
in 12/93 (12.9%) cases. The basic clinical and biologic data of
all patients are listed in Tables 1 and 2.Table 1 Initial patient’s characteristics in all AML group.
IDH1 m
n= 13
Age, years: median (range) 35 (19–6
TLCX109/L: median (range) 31(12.9–
PLTX109/L: median (range) 27(5–50
BM blasts: median (range) 58(20–8
FLT3-ITD, No. (%)
Mutant 5 (21.7)
Wild 8 (10.4)
Sex, No. (%)
Male 7(14.9)
Female 6(11.3)
FAB, No. (%) N= 12
M0 0
M1 2(8.3)
M2 3(7.3)
M3 2(25)
M4 3(17.6)
M5 2(50)
M7 0
Response to induction, No. (%) N= 9
CR 6(12.5)
Failure 3(11.5)
OS N= 13
Median (95% conﬁdence interval), months 1(0.43–1
Cumulative survival at 6 months 25.6%
* Indicates not applicable, –: no median because 50% of patients are still a
marrow blasts, CR: complete remission, OS: overall survival.Association of clinical characteristics with IDH1 mutations
IDH1-mutated patients showed no signiﬁcant difference in
age, sex, TLC, platelets counts, and percentage of BM blasts
as compared to IDH1-wild type group (Tables 1 and 2).
Association of FLT3-ITD with IDH1 mutations
In the non-APL group, IDH1 mutations were signiﬁcantly
associated with FLT3-ITD negativity (p= 0.03, Table 2).
Response to induction therapy
Within 28 of induction chemotherapy 48/100 (48%) of the
whole group and 43/93 (46.2%) of the non-APL group
achieved CR. There was no association with achievement of
CR. Response to induction therapy for IDH1-mutant and
IDH1-wild type AML, respectively, was as follows: CR,
12.5% and 87.5% in total AML group and 11.6%, and
88.4% for the non-APL group (Tables 1 and 2).
Survival analysis
The median follow-up period for survival of the entire group,
was relatively short; 2 months (range, 0.03–15 months). The
median (95% conﬁdence interval) OS for the whole group
was 2 (0.31–3.69). Those for non-APL group were 2 (0.99–
3.01). There was a trend for worse cumulative OS in the
IDH1 mutant group compared to IDH1 wild type group, espe-
cially when analysis was focused on non-APL AML (16.6%
versus 39.6%, p= 0.08) (Tables 1 and 2).utant IDH1 wild
n= 87
p-Value
0) 37 (16–60) 0.52
184) 22(0.4–273) 0.11
) 26(4–330) 0.68
7) 66(10–94) 0.48
18(78.3) 0.15
69(89.6)
40(85.1) 0.59
47(88.7)
N= 84
1(100) *
22(91.7)
38(92.7)
6(75)
14(82.4)
2(50)
1(100)
N= 65
42(87.5) 0.96
23(88.5)
N= 84
.57) 2(0.2–3.8) 0.18
41.6%
live, TLC: total leucocytic count, PLT: total platelet count, BM: bone
Table 2 Initial patient’s characteristics in non-APL AML group.
IDH1 mutant
n= 12
IDH1 wild
n= 81
P-Value
Age, years: median (range) 35(19–60) 37(16–60) 0.40
TLCX109/L: median (range) 86.5(12.9–148) 23(0.4–273) 0.11
PLTX109/L: median (range) 24.5(5–50) 27(4–163) 0.59
BM blasts: median (range) 64(20–87) 65(20–94) 0.79
FLT3-ITD, No. (%)
Mutant 5 (27.8) 13(72.2) 0.03
Wild 7 (9.3) 68(90.7)
Sex, No. (%)
Male 6(13.6) 38(86.4) 0.8
Female 6(12.2) 43(87.8)
FAB, No. (%) N= 11 N= 78
M0 0 1(100) *
M1 2(8.3) 22(91.7)
M2 4(9.5) 38(90.5)
M4 3(17.6) 14(82.4)
M5 2(50) 2(50)
M7 0 1(100)
Response to induction, No. (%) N= 8 N= 68
CR 5(11.6) 38(88.4) 0.90
Failure 3(12) 22(88)
OS
Median (95% conﬁdence interval), months 0.6(0.03–1.17) 2(0.61–3.39) 0.08
Cumulative survival at 6 months 16.6% 39.6%
* Indicates not applicable, – no median because 50% of patients are still alive, TLC, total leucocytic count, PLT, total platelet count, BM, bone
marrow blasts, CR, complete remission, OS overall survival.
Prognostic value of IDH1 mutations identiﬁed 47When we analyzed OS of the non-APL patients according
to the IDH1 and FLT3-ITD mutation status, we could not
ﬁnd a signiﬁcant difference between the different genotype
groups. Only 4 patients with IDH1 mutations were identiﬁed
among the IDH1 mutant/FLT3-ITD mutant, which prevented
reliable statistical analysis.Discussion
Although a series of elegant studies over the past decade have
identiﬁed a large set of mutations and overexpressed genes
with prognostic relevance in AML, in the clinical setting,
developing countries use cytogenetic abnormalities with or
without a relatively small set of gene-based tests to assign risk
in AML and to determine the post-remission therapy [23]. The
requirement for expensive technologies like high-throughput
massively parallel DNA sequencing is the main reason behind
the relative paucity of clinically used biomarkers in these
countries.
Recently, IDH1 gene was identiﬁed as a new prognostic
marker in CN-AML using next generation sequencing [24].
More recently, an interaction between IDH1 mutations and
the genotype of mutated NPM1 without FLT3-ITD was sug-
gested [6].
In this work, we conﬁrmed IDH1 mutation as a new recur-
rent genetic alteration in adult AML. We extended the results
of the pivotal study of Meyer et al. [16] on glioma patients by
adapting PCR and restriction-based detection of IDH1 muta-
tion to include AML patients. The dCAPS mutation analysis
provided a rapid and inexpensive approach for screening of
IDH1 mutations. The use of laboratory equipment commonin all molecular diagnostic laboratories was the major advan-
tage of this approach.
We have determined the presence or absence of mutation in
all patients but unfortunately we could not determine the spe-
ciﬁc amino acid (AA) exchange of each mutation detected be-
cause of the small amount of available residual DNA.
We could not validate our data with genomic sequencing,
however Meyer et al. [16] sequenced 60 glioma tumors and
compared results with their PCR- and restriction endonuclease
based detection assay, and no discrepancies between the tests
were detected.
The overall frequency of IDH1 mutation for unselected
group of AML varies from 4% to 9.3% [4,13]. In this study,
we report a slightly higher frequency (13%) of IDH1 mutation
in AML.
IDH1 R132 is mainly limited to CN-AML, for this reason,
the frequency of the IDH1 mutation in AMLs is likely to vary
from one study to another, depending on the percentage of
AML cases with abnormal karyotype [25]. Our patients were
cytogenetically heterogeneous except for 7 patients with posi-
tive PML/RARA. Different variable inclusion criteria of the
study samples, different age distribution, and racial differences
may also reﬂect the frequency discrepancies among various
studies.
Despite the recent interest in IDH1 mutations in AML, a
limited amount of information is available about morphologic
features. Previous studies have suggested an association with
FAB M1 and M2 subtype [24–26].
Although, IDH1 mutation was previously reported to be
strongly associated with CN-AML [6,10,24,27], we found a
high frequency of IDH1 mutation in 2/8 APL patients with t
(15; 17) (25%). This ﬁnding underlines the apparent associa-
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niﬁcantly higher frequency (31%) was observed by Chotirat et
al. [2]. Several recurrent transcription factors such as AML1/
ETO and CBFß/MYH11 were recently shown to coexist with
IDH1 mutations in AML [13]. The prognostic signiﬁcance of
IDH1 mutation in APL needs further studies.
The frequent presence of coexisting mutations like NPM1,
FLT3, CEBPA, RAS, and KIT with IDH1 mutations supports
the ‘‘multiple hit’’ model of mutation acquisition in AML. Be-
cause IDH1 mutations act by accumulation of metabolite, they
seem to represent a completely new type of mechanism in
AML leukemogenesis. Unlike previous studies [1–2,9], we
did not ﬁnd signiﬁcant association between IDH1 mutations
and FLT3-ITD positivity. In fact, IDH1 was signiﬁcantly less
frequent in patients with activating FLT3-ITD mutation. Our
ﬁndings were however similar to other studies [6,25,28].
While the prognostic implication of IDH1 mutation status
in patients with gliomas is well described, its importance in
AML remains a matter of discussion. In this work, IDH1 mu-
tant patients showed no signiﬁcant difference when compared
to IDH1 negative patients in response to therapy, relapse risk
or OS when the total AML group was analyzed. Similar results
were obtained by other researchers [9,6,28]. However, the ad-
verse effect of IDH1 mutations on OS was more obvious in
the non-APL group (p= 0.08) which was homogenously trea-
ted and none of our patients had BMT, thereby, supporting
the notion that the clinical importance of molecular aberra-
tions may vary according to therapeutic contexts in which they
are evaluated [4].
Although the identiﬁcation of single gene mutations with
impact on outcome is of clinical and biologic importance,
the main goal of mutational studies should be to inform and
improve prognostic algorithm in AML [23].
Recent mutational studies have been able to increasingly re-
ﬁne the prognosis in patients with intermediate risk and/or
CN-AML, and to analyze the prognostic effect for IDH1
mutations in molecular subtypes with FLT3 and NPM1 muta-
tions [10,23,28]. In this regard we wish to note that during sta-
tistical analysis for OS in IDH1/FLT3-ITD molecular
subtypes, the number of patients in each subgroup became
increasingly low, even though this study was performed on
100 patients, which limits the statistical power of this analysis,
and prohibits the interesting exploratory analysis for these
mutations.
However it seems that, the issue surrounding the IDH1
mutations is far more complicated than the simple presence
or absence of the mutations, and need to be put in context
of other collaborating factors especially FLT3 and NPM1
mutations status. In addition, the favorable effect of NPM1
mutations could be restricted to patients with co-occurring
NPM1 and IDH1 [4,23,29].
Conclusion
The PCR-RFLP method allows for a fast, inexpensive, and
sensitive method for the detection of IDH1 mutations in
AML. IDH1 mutations are recurring genetic alterations in
AML. Testing for IDH1 mutations should be included in the
routine molecular analysis of AML to conﬁrm the relevance
of these mutations as novel genetic markers that may allow
for additional risk stratiﬁcation of an important subset ofAML. IDH1 mutations may have unfavorable impact on clin-
ical outcome in young adults (16–60 years) homogenously
treated de novo AML.
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